Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.55 |
| ▸ | RECQL | P46063 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.55 |
| ▸ | LCK | P06239 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7433937 | 1.00 | KDM6B (0.57) | KDM6BALOX15KDM4EHIF1AHSD17B10 | |
| SCHEMBL22364281 | 1.00 | KDM6B (0.57) | KDM6BALOX15KDM4EHIF1AHSD17B10 | |
| SCHEMBL29759443 | 0.88 | KDM6B (0.54) | KDM6BALOX15KDM4EHIF1AHSD17B10 | |
| SCHEMBL22364280 | 0.88 | KDM6B (0.54) | KDM6BALOX15KDM4EHIF1AHSD17B10 | |
| SCHEMBL29926699 | 0.85 | KDM6B (0.51) | KDM6BALOX15KDM4EHIF1AHSD17B10 | |
| SCHEMBL5207224 | 0.85 | FOLH1 (0.46) | KDM6BALOX15KDM4EHIF1AHSD17B10 | |
| SCHEMBL31028433 | 0.85 | KDM6B (0.51) | KDM6BALOX15KDM4EHIF1AHSD17B10 | |
| SCHEMBL25489225 | 0.85 | MME (0.57) | KDM6BALOX15KDM4EHIF1AHSD17B10 | |
| Hydrochloric Acid SCHEMBL10782448 | 0.84 | KDM6B (0.61) | KDM6BALOX15KDM4EHIF1AHSD17B10 | |
| SCHEMBL6340344 | 0.84 | KDM6B (0.57) | KDM6BALOX15KDM4EHIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139250-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY TARGETING ONCOGENIC TRANSFER RNAS | THE CHILDRENS MEDICAL CENTER CORP (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260091144-A1 | BIO-ACTIVATED REPORTERS TO VISUALIZE, IN REAL TIME, SPECIFIC GENE THERAPY PRODUCTS | UNIV NORTHWESTERN (US) | 2026-04-02 | — | — | US | disclosed |
| US-12508328-B2 | Bio-activated reporters to visualize, in real time, specific gene therapy products | NORTHWESTERN UNIVERSITY (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4551702-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY TARGETING ONCOGENIC TRANSFER RNAS | The Children's Medical Center Corporation (US) | 2025-05-14 | — | — | EP | disclosed |
| US-11878057-B2 | Immunomodulatory lipopolysaccharide compositions | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-01-23 | — | — | US | disclosed |
| WO-2024011118-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY TARGETING ONCOGENIC TRANSFER RNAS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-3541368-B1 | IMAGEABLE PARTICLES, METHODS OF MAKING AND METHODS OF USE THEREOF | US HEALTH (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11382990-B2 | Imageable polymers, methods of making and methods of use thereof | THE USA, AS REPRESENTED BY THE SECRETARY, DHHS (US) | 2022-07-12 | — | — | US | disclosed |
| WO-2022125956-A1 | IMMUNOMODULATORY LIPOPOLYSACCHARIDE COMPOSITIONS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220184206-A1 | IMMUNOMODULATORY LIPOPOLYSACCHARIDE COMPOSITIONS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382990-B2 | Imageable polymers, methods of making and methods of use thereof | PUF60, PBRM1, PCBP1 | KDM6B 591/4885ALOX15 4457/4885KDM4E 1954/4885 |
| US-20260139250-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY TARGETING ONCOGENIC TRANSFER RNAS | TRDMT1, METTL16, TRMT1 | KDM6B 1252/4885ALOX15 4577/4885KDM4E 821/4885 |
| US-12508328-B2 | Bio-activated reporters to visualize, in real time, specific gene therapy products | GAA, GUSB, GBA3 | KDM6B 1667/4885ALOX15 4528/4885KDM4E 4136/4885 |
| US-20260091144-A1 | BIO-ACTIVATED REPORTERS TO VISUALIZE, IN REAL TIME, SPECIFIC GENE THERAPY PRODUCTS | GAA, GUSB, GBA3 | KDM6B 1230/4885ALOX15 4597/4885KDM4E 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.